美尔雅(600107) - 2025 Q2 - 季度业绩预告

Hubei Meiya Co., Ltd. 2025 Semi-Annual Performance Forecast Core Summary of Performance Forecast The company projects continued losses for H1 2025, with net profit attributable to parent shareholders estimated between -36 million and -19.5 million yuan, and a larger loss for non-recurring net profit Estimated Performance for H1 2025 | Indicator | Estimated Amount (RMB) | Year-over-Year Growth Rate | | :--- | :--- | :--- | | Net Profit Attributable to Parent Shareholders | -36 million to -19.5 million yuan | -31.00% to 29.04% | | Net Profit Attributable to Parent Shareholders (Excluding Non-Recurring Items) | -46 million to -24.8 million yuan | -33.86% to 27.83% | - This performance forecast is a preliminary estimate by the company's financial department and has not been audited by an accounting firm[4] Prior Period Performance Comparison In H1 2024, the company reported a net loss of -27.48 million yuan attributable to parent shareholders, with non-recurring net profit at -34.37 million yuan, indicating potential for either slight improvement or further loss in H1 2025 Actual Performance for H1 2024 | Indicator | Actual Amount for H1 2024 (RMB) | | :--- | :--- | | Net Profit Attributable to Parent Shareholders | -27.48 million yuan | | Net Profit Attributable to Parent Shareholders (Excluding Non-Recurring Items) | -34.37 million yuan | | Basic Earnings Per Share | -0.08 yuan/share | Analysis of Performance Change The performance change is primarily due to a decrease in operating revenue, driven by the disposal of a pharmaceutical subsidiary and a decline in the core apparel business, alongside a significant reduction in investment income compared to the prior year - Operating revenue decreased due to the disposal of equity in Qinghai Zhongyou Health Huijia Pharmaceutical Chain Co., Ltd., resulting in a reduction of approximately 30 million yuan in pharmaceutical segment revenue[6][7] - Apparel business revenue declined compared to the prior year[7] - Investment income decreased by approximately 10 million yuan year-over-year, primarily from debt restructuring related to a prior year's subsidiary equity transfer, which generated higher income[7] - Company strategy includes intensifying market development and implementing cost reduction and efficiency improvement measures to enhance operating performance[7] Risk Warning and Other Notes The company confirms no material uncertainties affecting the accuracy of this preliminary performance forecast, emphasizing that final financial data will be disclosed in the 2025 semi-annual report, urging investors to exercise caution - The company states there are no significant uncertainties affecting the accuracy of this performance forecast[8] - Final financial data will be subject to the company's 2025 semi-annual report, and investors are advised to be aware of investment risks[9]